Updates on the management of Glioblastoma

Glioblastoma is the most common primary malignant brain tumor, representing approximately 48% of all primary central nervous system malignant tumors. Despite advances in multidisciplinary treatment for glioblastoma including surgery, radiation therapy, systemic therapy such as chemotherapy, locoregional therapies, immunotherapies, other targeted therapies, and supportive care, the overall prognosis is poor, with an average survival of 14 months. Furthermore, it is associated with a progressive decline in quality of life and neurologic function impacting the patients and their families. The new era of molecular biology and targeted therapies such as immunotherapy may have a lot of promising chances in developing more effective and tolerable treatments to combat this deadly disease.

This Research Topic will focus on the management of glioblastoma in the adult population from different perspectives such as chemotherapy, radiotherapy, immunotherapy, glioma stem cell therapy, nanotechnology, endovascular treatment, and novel surgical management tools and concepts. This includes basic science and clinical studies.

For bioinformatics/in silico studies (including but not limited to candidate biomarkers), there must be independent validation in clinical samples obtained from participating institutions and/or functional validation in at least two recognized glioblastoma cell lines in vitro and/or in vivo.